RxDoctor Payments Data

Elias Bou Prieto, MD

Cardiovascular Disease · Bayamon, PRNPI 1013110485

Payments from drug & device makers

$2,533in general payments, 2019–2025

Across 37 payments — averaging $68.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Abbott$286
  • Johnson & Johnson$234
  • AbbVie$108
  • Boehringer Ingelheim$68
  • AstraZeneca$57
  • plus $20 from 1 others

What the payments were for

  • Food & beverage$2,533100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic20$1,759
Abbott4$286
Johnson & Johnson5$234
AbbVie1$108
Boehringer Ingelheim3$68
AstraZeneca3$57
PBG Puerto Rico LLC1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,533 in reported general payments places this provider in the 45th percentile of 267 cardiovascular disease providers in Puerto Rico.

See all cardiovascular disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$4,676
Medicare patients
19
Services billed
43

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SynthroidLevothyroxine Sodium13$1,831
Candesartan Cilexetil14$1,496
Metoprolol Succinate36$937
Atorvastatin Calcium39$551
Losartan Potassium38$529
Lisinopril15$160
Amlodipine Besylate19$90

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid$108$1,83113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 267 cardiovascular disease providers in Puerto Rico.

Other cardiovascular disease in Bayamon

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →